Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-06

Clinical Trial Update: Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ponatinib as frontline therapy for chronic myeloid leukemia in accelerated phase; the study was terminated and results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Iclusig (ponatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2019-09-06